Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

LTRN

Lantern Pharma Inc

Dec 11 • 04:00PM ET

3.84

Dollar change -0.14
Percentage change -3.52	%

Healthcare • Biotechnology • USA • NASD

Peers: EXAI DNLI FATE IMTX KRYS RAPT RPTX XERS ARDX

| Held by: VTI VXF MEDX IWC DFAT DFSU DFAC DXUV DCOR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.77	Insider Own	25.54%	Shs Outstand	10.78M	Perf Week	0.26%
Market Cap	41.41M	Forward P/E	-	EPS next Y	-1.74	Insider Trans	0.00%	Shs Float	8.03M	Perf Month	9.40%
Income	-19.09M	PEG	-	EPS next Q	-0.51	Inst Own	12.39%	Short Float	1.99%	Perf Quarter	1.32%
Sales	0.00M	P/S	-	EPS this Y	-30.27%	Inst Trans	3.76%	Short Ratio	3.01	Perf Half Y	-32.04%
Book/sh	2.47	P/B	1.56	EPS next Y	9.40%	ROA	-48.91%	Short Interest	0.16M	Perf Year	-2.04%
Cash/sh	2.60	P/C	1.48	EPS next 5Y	-	ROE	-53.03%	52W Range	2.79 - 11.99	Perf YTD	-10.28%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-39.81%	ROI	-71.53%	52W High	-67.97%	Beta	1.52
Dividend TTM	-	Quick Ratio	8.31	Sales past 5Y	0.00%	Gross Margin	-	52W Low	37.63%	ATR (14)	0.39
Dividend Ex-Date	-	Current Ratio	8.31	EPS Y/Y TTM	-27.05%	Oper. Margin	-	RSI (14)	57.56	Volatility	15.67% 10.51%
Employees	21	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	20.50
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-43.75%	Payout	-	Rel Volume	0.74	Prev Close	3.98
Sales Surprise	-	EPS Surprise	25.00%	Sales Q/Q	-	Earnings	Nov 07 AMC	Avg Volume	53.12K	Price	3.84
SMA20	13.07%	SMA50	11.49%	SMA200	-21.92%	Trades		Volume	39,229	Change	-3.52%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-07-21	Initiated	H.C. Wainwright	Buy	$32

Dec-10-24 10:40AM	AI-Powered Cancer Solutions: Lantern Pharma (LTRN) Launches Phase 2 Trial in Taiwan (Insider Monkey)
Dec-09-24 12:21PM	Lantern Pharma starts dosing in Taiwan in non-smoker lung cancer trial (Clinical Trials Arena)
08:15AM	Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC Clinical Trial of LP-300 in Never-Smoker NSCLC Patients (Business Wire)
Dec-07-24 01:59AM	Lantern Pharma Inc. (LTRN) Receives Second FDA Fast Track Designation for LP-184 in Triple Negative Breast Cancer (Insider Monkey)
Dec-03-24 08:00AM	Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC) (Business Wire)
08:45AM	Loading…
Nov-26-24 08:45AM	Lantern Pharma and Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality (Business Wire)
08:45AM	Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality (Business Wire)
Nov-19-24 08:00AM	Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC Clinical Trial of LP-300 in Never-Smoker NSCLC Patients (Business Wire)
Nov-08-24 06:03PM	Lantern Pharma Inc (LTRN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising ... (GuruFocus.com) +12.28% -8.59%
Nov-07-24 04:05PM	Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates (Business Wire)
Nov-05-24 08:00AM	Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board (Business Wire)
Oct-31-24 08:00AM	Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET (Business Wire)
Oct-23-24 08:45AM	Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024 (Business Wire)
Oct-21-24 08:00AM	Lantern Pharma to Host & Participate in Two Public Webinars During October (Business Wire)
Oct-15-24 09:07AM	Lantern Pharmas Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA (Business Wire)
05:56PM	Loading…
Oct-09-24 05:56PM	Lantern Pharma Inc (LTRN) Q2 2024 Earnings Call Highlights: Promising Clinical Trials and ... (GuruFocus.com)
Sep-23-24 08:00AM	Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Childrens Cancers (Business Wire)
Aug-31-24 02:02PM	Lantern Pharma Inc. (LTRN): A Penny Stock That Will Make You a Millionaire (Insider Monkey)
Aug-08-24 04:01PM	Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates (Business Wire) -7.68%
Aug-07-24 09:31AM	Lantern Pharma Highlights Promising Preclinical Results of LP-184's Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024 (Business Wire) +12.26%
Aug-05-24 08:00AM	Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort (Business Wire) -5.88%
Aug-01-24 08:00AM	Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ET (Business Wire)
Jul-10-24 08:30AM	Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184 (Business Wire)
Jun-12-24 07:30AM	Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284 (Business Wire)
May-23-24 11:51AM	Pancreatic Cancer Battle Intensifies: Biotech Innovations Aim to Boost Survival Rates (PR Newswire)
May-09-24 04:02PM	Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights (Business Wire) +5.09% -9.54%
May-06-24 06:41AM	Lantern Pharma and Oregon partner to develop cancer treatment (Pharmaceutical Technology) +11.38%
04:37AM	Lantern Pharma, Oregon Therapeutics Partner to Develop AI-Driven Cancer Drug Collaboration (MT Newswires)
03:00AM	Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 A Potent Inhibitor of Cancer Metabolism (Business Wire)
May-02-24 07:30AM	Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET (Business Wire)
06:00AM	Loading…
May-01-24 06:00AM	3 Machine Learning Stocks with the Potential to Make You an Overnight Millionaire (InvestorPlace) +5.69%
Apr-24-24 08:00AM	Lantern Pharma Launches "Webinar Wednesdays" Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development (Business Wire) -6.76%
Apr-22-24 08:12AM	Lantern Pharma Receives Regulatory Approval to Expand Harmonic Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan (Business Wire) +7.12%
Apr-10-24 08:45AM	Software Segment of Global A.I. Healthcare Billion Dollar Market Expected to Have Fastest Growth (PR Newswire)
Mar-20-24 09:00AM	Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028 (GlobeNewswire) +17.49%
Mar-19-24 09:06AM	Lantern Pharma Inc. (NASDAQ:LTRN) Q4 2023 Earnings Call Transcript (Insider Monkey) -24.80%
Mar-18-24 08:53PM	LTRN Stock Earnings: Lantern Pharma Beats EPS for Q4 2023 (InvestorPlace) +14.48%
05:32PM	Lantern Pharma Inc Reports Progress and Financials for FY 2023 (GuruFocus.com)
04:02PM	Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights (Business Wire)
Mar-15-24 08:00AM	Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284 (Business Wire) +18.37%
Mar-11-24 07:30AM	Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET (Business Wire) -23.58%
Mar-07-24 06:17AM	11 Best Artificial Intelligence Stocks Under $20 According To Hedge Funds (Insider Monkey) +21.13%
Mar-05-24 08:01AM	Lantern To Participate in H.C Wainwright & Co.s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference (Business Wire) +5.95%
Mar-04-24 08:01AM	Lantern Pharma's A.I. Platform, RADR, Surpasses 60 Billion Data Points Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines (Business Wire) +9.40%
Feb-20-24 08:01AM	3 AI Powerhouses Predicted to Soar 500% in the Next Tech Boom (InvestorPlace)
Feb-15-24 08:01AM	Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers (Business Wire)
Jan-17-24 07:30AM	Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer (Business Wire)
Dec-13-23 08:05AM	The 3 Most Undervalued AI Penny Stocks to Buy in December (InvestorPlace)
Nov-30-23 08:00AM	FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL) (Business Wire)
Nov-10-23 11:31AM	Lantern Pharma Inc. (NASDAQ:LTRN) Q3 2023 Earnings Call Transcript (Insider Monkey) -11.53%
Nov-08-23 06:43PM	Lantern Pharma Inc (LTRN) Reports Q3 2023 Financial Results and Provides Operational Updates (GuruFocus.com) +33.21%
04:01PM	Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights (Business Wire)
Nov-01-23 08:00AM	Lantern Pharma to Report Third Quarter 2023 Operating & Financial Results on November 8th, 2023 at 4:30 p.m. ET (Business Wire)
Oct-24-23 04:03PM	The 7 Most Undervalued AI Penny Stocks to Buy: October 2023 (InvestorPlace)
Oct-10-23 08:00AM	Lantern Pharma to Present at the ThinkEquity Conference on October 19 at 1:30 p.m. ET (Business Wire) +10.32%
Oct-03-23 08:00AM	Lantern Pharma Announces Publication in Clinical Cancer Research Highlighting the Enhanced Efficacy of LP-184 in Glioblastoma (Business Wire) -8.23%
Sep-29-23 07:40AM	LTRN: Spotlight on LP-184 & 284 (Zacks)
Sep-25-23 08:30AM	Lantern Pharma Announces First Patient Dosed in the Phase 1 Study for LP-184 in Advanced Solid Tumors (Business Wire)
Sep-18-23 09:00AM	Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkins Lymphomas (Business Wire)
Sep-14-23 09:09AM	The 3 Most Undervalued Machine Learning Stocks to Buy in September 2023 (InvestorPlace)
Aug-31-23 08:00AM	Lantern Pharma to Present Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-284 in Non-Hodgkins Lymphomas at the Society of Hematologic Oncology Annual Meeting (Business Wire)
Aug-28-23 05:32PM	3 AI Stocks That Still Trade Under $10 Per Share (InvestorPlace)
08:00AM	Lantern Pharma Expands AI Capabilities of RADR® Platform to Accelerate the Clinical Development of Immune Checkpoint Inhibitors (Business Wire)
Aug-23-23 06:00PM	The 3 Most Undervalued Machine Learning Stocks to Buy Now: August 2023 (InvestorPlace)
Aug-14-23 08:30AM	Lantern Pharma Receives Notice of US Patent Allowance for Drug Candidate LP-184 for the Treatment of Rare Pediatric Brain Cancer, ATRT (Business Wire)
Aug-10-23 08:37AM	LTRN: 2Q:23 Quarterly Update (Zacks Small Cap Research) +7.07%
Aug-09-23 04:01PM	Lantern Pharma Reports Second Quarter 2023 Financial Results and Operational Highlights (Business Wire)
09:11AM	3 AI Penny Stocks With the Potential to Make Your Financial Dreams Come True (InvestorPlace)
Aug-08-23 03:06PM	3 AI Stocks Youll Regret Not Buying Soon (InvestorPlace)
Aug-02-23 12:45PM	RedChip Launches 'Small Stocks, Big Money' Podcast (ACCESSWIRE)
08:00AM	Lantern Pharma to Report Second Quarter 2023 Operating & Financial Results on August 9, 2023 at 4:30 p.m. ET (Business Wire)
Aug-01-23 07:30PM	3 AI Stocks to Buy Under $10 in August 2023 (InvestorPlace) +5.62%
Jul-30-23 02:45PM	7 AI Penny Stocks that Could Hit $5 Soon (InvestorPlace)
Jul-17-23 08:00AM	Lantern Pharma to Participate and Present at Multiple Upcoming Conferences (Business Wire)
Jun-26-23 08:30AM	Oncotarget Publishes New Data by Lantern Pharma, an AI Company Developing Cancer Therapies, Further Supporting Clinical Advancement of LP-284, a Novel Synthetically Lethal Drug Candidate for Non-Hodgkins Lymphomas (Business Wire)
Jun-12-23 08:30AM	Lantern Pharma Receives FDA Clearance of IND Application for Drug Candidate LP-184 in Solid Tumors (Business Wire) +7.96%
Jun-08-23 09:00AM	Lantern Pharma Leverages AI Platform, RADR®, to Develop Breakthrough Antibody Drug Conjugates (ADCs) in Collaboration with Bielefeld University (Business Wire)
May-19-23 06:50AM	3 Penny Stocks to Buy as the AI Sector Transforms Every Industry in 2023 (InvestorPlace) +6.38%
May-17-23 08:00AM	Lantern Pharma to Present at the Lytham Partners Spring 2023 Investor Conference Thursday, May 18th at 9:00 a.m. ET (Business Wire)
May-10-23 09:59AM	LTRN: First Harmonic Patient Dosed (Zacks Small Cap Research)
May-09-23 04:01PM	Lantern Pharma Reports First Quarter 2023 Financial Results and Operational Highlights (Business Wire) +5.66%
May-03-23 09:00AM	Lantern Pharma Selects REPROCELL USA to Provide Support for the Phase 2 Harmonic Clinical Trial (PR Newswire) -6.05%
May-02-23 04:01PM	Lantern Pharma to Report First Quarter 2023 Operating & Financial Results on May 9, 2023 at 4:30 p.m. ET (Business Wire)
07:30AM	Lantern Pharma Develops Top-Ranked AI Algorithms to Predict the Blood-Brain-Barrier Permeability of Any Compound (Business Wire)
Apr-13-23 07:30AM	Lantern Pharma Receives Notice of Allowance for Composition of Matter Patent Covering Drug Candidate LP-284 (Business Wire)
Mar-28-23 08:00AM	Lantern Pharma Announces First Patient Dosed in the Phase 2 Study, Harmonic, for LP-300 in Never Smokers with Advanced Non-Small Cell Lung Cancer (Business Wire)
Mar-24-23 07:15AM	Lantern Pharma Inc. (NASDAQ:LTRN) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-22-23 11:50AM	We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate (Simply Wall St.)
11:45AM	LTRN: 2022 Financial and Operational Results (Zacks Small Cap Research)
Mar-21-23 04:01PM	Lantern Pharma to Present at Upcoming Scientific Conferences and Webinars (Business Wire) -5.38%
12:11PM	Q4 2022 Lantern Pharma Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-20-23 04:01PM	Lantern Pharma Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Operational Highlights (Business Wire)
Mar-15-23 08:00AM	Lantern Pharma to Present at the American Association for Cancer Research (AACR) Annual Meeting (Business Wire)
Mar-13-23 08:00AM	Lantern Pharma to Report Fourth Quarter and Fiscal Year 2022 Operating & Financial Results on March 20, 2023 at 4:30 p.m. ET (Business Wire) +9.30%
06:16AM	Lantern Pharma said it had no exposure to SVB or Signature Bank, after stock plunged last week (MarketWatch)
06:00AM	Lantern Pharma Confirms It Had No Exposure to Silicon Valley Bank (SVB), Silvergate Bank, or Signature Bank (Business Wire)
Mar-09-23 08:00AM	Lantern Pharma Announces New Data and Development Focus for LP-100 with PARP Inhibitors (Business Wire)
Mar-08-23 08:00AM	Lantern Pharma to Host Virtual KOL Webinar on Synthetic Lethality, the Powerful Mechanism of Action Behind Several of Lanterns Drug Candidates, Featuring Zoltan Szallasi, M.D. (Business Wire)
Mar-06-23 08:00AM	Lantern Pharma Announces Formation of Starlight Therapeutics to Advance Transformative Therapies for CNS (Central Nervous System) and Brain Cancers (Business Wire)
Mar-02-23 08:00AM	Lantern Pharma Expands Clinical Leadership Team to Further Advance its Ongoing and Upcoming Clinical Trials (Business Wire)

Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-100, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fletcher Aaron G.L.	10% Owner	May 24 '24	Sale	6.33	20,000	126,600	57,467	May 28 04:30 PM
Fletcher Aaron G.L.	10% Owner	May 23 '24	Sale	6.25	10,000	62,500	59,326	May 28 04:30 PM
Fletcher Aaron G.L.	10% Owner	Feb 28 '24	Sale	4.85	74,297	360,340	62,088	Feb 29 09:54 PM
Fletcher Aaron G.L.	10% Owner	Feb 27 '24	Sale	4.40	50,000	220,000	68,997	Feb 29 09:54 PM
Fletcher Aaron G.L.	10% Owner	Feb 29 '24	Sale	4.87	19,703	95,954	60,256	Feb 29 09:54 PM
Kreis Leslie W.	10% Owner	Feb 28 '24	Sale	4.85	74,297	360,340	62,088	Feb 29 09:54 PM
Kreis Leslie W.	10% Owner	Feb 27 '24	Sale	4.40	50,000	220,000	68,997	Feb 29 09:54 PM
Kreis Leslie W.	10% Owner	Feb 29 '24	Sale	4.87	19,703	95,954	60,256	Feb 29 09:54 PM
Fletcher Aaron G.L.	10% Owner	Jan 17 '24	Sale	4.20	58,889	247,334	73,646	Jan 19 04:31 PM
Kreis Leslie W.	10% Owner	Jan 17 '24	Sale	4.20	58,889	247,334	73,646	Jan 19 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LTRN

Lantern Pharma Inc

Upgrade your FINVIZ experience